Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. SAVA Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Cassava Sciences (SAVA)

Market Price (9/17/2025): $2.1 | Market Cap: $101.4 Mil
Sector: Health Care | Industry: Biotechnology

Cassava Sciences (SAVA)

Market Price (9/17/2025): $2.1
Market Cap: $101.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -111%		 Weak multi-year price returns
2Y Excs Rtn is -137%, 3Y Excs Rtn is -156%		 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1  Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -131 Mil
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -126%
3   High stock price volatility
Vol 12M is 119%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -111%
1 Weak multi-year price returns
2Y Excs Rtn is -137%, 3Y Excs Rtn is -156%
2 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%
3 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -131 Mil
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -126%
6 High stock price volatility
Vol 12M is 119%

Market Valuation

 9/17/252024202320222021
Share Price CYE$2.10$2.36$22.51$29.54$43.70
Market Cap CYE ($ Mil)101.4113.5949.81,204.71,746.5
Total Debt ($ Mil)0.00.00.00.10.2
Total Cash ($ Mil)112.4128.6121.1201.0233.4
Enterprise Value ($ Mil)-10.9113.5949.81,204.81,746.7
Valuation Ratios     
P/S TTM0.00.00.00.00.0
P/EBIT TTM-0.8-0.8-8.8-14.6-52.4
P/E TTM-0.8-4.5-9.7-15.6-53.2
Sector Ratios     
P/S TTM (Sector)3.73.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/17/2520242023
Share Price CYE$2.10$2.36$22.51
Market Cap CYE ($ Mil)101.4113.5949.8
Total Debt ($ Mil)0.00.00.0
Total Cash ($ Mil)112.4128.6121.1
Enterprise Value ($ Mil)-10.9113.5949.8
Valuation Ratios   
P/S TTM0.00.00.0
P/EBIT TTM-0.8-0.8-8.8
P/E TTM-0.8-4.5-9.7
Sector Ratios   
P/S TTM (Sector)3.73.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
SAVA Return31%541%-32%-24%-90%-11%-59%
Peers Return22%57%7%1%1%6%123%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BIIB, AVXL, ABBV, AMGN, GILD. See SAVA Returns vs. Peers.
[3] 2025 data is for the year up to 9/16/2025 (YTD)

Better Bets than Cassava Sciences (SAVA)

 SAVABetter Performance than SAVA
MetricValueIndustry (Biotechnology)
Total Yield-122.0%ABBV (3.9%), AMGN (7.9%), GILD (7.4%), VRTX (3.6%), REGN (7.7%)
 SAVABetter Performance than SAVA
MetricValueAll Other Sectors
Total Yield-122.0%NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.8%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Cassava Sciences (SAVA) Stock: 40% of days in last 3 months had 1% or greater fluctuation  
2Day 0 of Loss Streak for Cassava Sciences Stock with 0% Return (vs. -89% YTD) [12/20/2024]Notification 
3Day 0 of Loss Streak for Cassava Sciences Stock with 0% Return (vs. -88% YTD) [12/14/2024]Notification 
4Cassava Sciences vs. S&P500 CorrelationCorrelation 
5Cassava Sciences Price VolatilityVolatility 
6Day 5 of Loss Streak for Cassava Sciences Stock with -39% Return (vs. -4.5% YTD) [8/12/2024]Notification 
7Cassava Sciences Market PriceMarket Price 
8Day 6 of Loss Streak for Cassava Sciences Stock with -46% Return (vs. -55% YTD) [7/8/2024]Notification 
9Day 5 of Loss Streak for Cassava Sciences Stock with -18% Return (vs. -17% YTD) [3/9/2024]Notification 
10Day 5 of Loss Streak for Cassava Sciences Stock with -17% Return (vs. -16% YTD) [12/22/2023]Notification 
11ARTICLES  
12Will Cassava Sciences Stock Continue To See Lower Levels? November 18th, 2021
13What’s Happening With Cassava Sciences Stock? September 27th, 2021
14After A 30% Fall Cassava Stock Is Likely To See Lower Levels August 26th, 2021
15Will The Rally In Cassava Sciences Stock Continue After A Large 66% Rise In A Month? June 21st, 2021
16Can Rally In Cassava Sciences Stock Continue? March 18th, 2021
Title
0DASHBOARDS
1Will Cassava Sciences Stock Continue To See Lower Levels?
2What’s Happening With Cassava Sciences Stock?
3After A 30% Fall Cassava Stock Is Likely To See Lower Levels
4Will The Rally In Cassava Sciences Stock Continue After A Large 66% Rise In A Month?
5Can Rally In Cassava Sciences Stock Continue?
6ARTICLES
7Cassava Sciences (SAVA) Stock: 40% of days in last 3 months had 1% or greater fluctuation
8Day 0 of Loss Streak for Cassava Sciences Stock with 0% Return (vs. -89% YTD) [12/20/2024]
9Day 0 of Loss Streak for Cassava Sciences Stock with 0% Return (vs. -88% YTD) [12/14/2024]
10Cassava Sciences vs. S&P500 Correlation
11Cassava Sciences Price Volatility
12Day 5 of Loss Streak for Cassava Sciences Stock with -39% Return (vs. -4.5% YTD) [8/12/2024]
13Cassava Sciences Market Price
14Day 6 of Loss Streak for Cassava Sciences Stock with -46% Return (vs. -55% YTD) [7/8/2024]
15Day 5 of Loss Streak for Cassava Sciences Stock with -18% Return (vs. -17% YTD) [3/9/2024]
16Day 5 of Loss Streak for Cassava Sciences Stock with -17% Return (vs. -16% YTD) [12/22/2023]

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO9734.4% 
3CHSNChanson International7565.0%-99.3%
4LNZALanzaTech Global7287.5%-86.0%
5QMMMQMMM3031.7%6775.0%
6OESXOrion Energy Systems1497.9%22.9%
7CURXCuranex Pharmaceuticals1401.6%1401.6%
8ENTOEntero Therapeutics565.6%117.6%
9PTNMPitanium553.2% 
10WLDSWearable Devices449.5%-30.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-92.2%-95.0%
2STFSStar Fashion Culture-92.2%-97.8%
3ELPWElong Power-91.6%-76.7%
4NXTTNext Technology-89.6%-95.1%
5NAKAKindly MD-89.0% 
6BINIBollinger Innovations-88.9%-100.0%
7JEM707 Cayman-88.4%-98.2%
8YAASYouxin Technology-82.5%-98.3%
9NEONNeonode-82.0%-50.2%
10NVNOenVVeno Medical-81.5%-69.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Cassava Sciences

Financials

SAVABIIBAVXLABBVAMGNGILDMedian
NameCassava .Biogen Anavex L.AbbVie Amgen Gilead S. 
Mkt Price2.09143.688.96216.26273.08110.86127.27
Mkt Cap0.121.00.8382.3146.9138.079.5
Rev LTM09,816058,32834,91728,86219,339
Op Inc LTM-1312,274-5613,6958,19210,7975,233
FCF LTM-962,296-3718,23910,6059,3695,832
FCF 3Y Avg-871,667-3120,2738,5908,3975,032
CFO LTM-962,582-3719,28312,0139,8686,225
CFO 3Y Avg-861,968-3121,1549,7538,9495,459

Growth & Margins

SAVABIIBAVXLABBVAMGNGILDMedian
NameCassava .Biogen Anavex L.AbbVie Amgen Gilead S. 
Rev Chg LTM-1.6%-6.1%12.9%3.8%4.9%
Rev Chg 3Y Avg--3.1%-0.6%10.0%1.6%1.1%
Rev Chg Q-6.1%-6.6%9.4%1.8%6.4%
QoQ Delta Rev Chg LTM-1.5%-1.7%2.3%0.4%1.6%
Op Mgn LTM-23.2%-23.5%23.5%37.4%23.5%
Op Mgn 3Y Avg-23.4%-27.2%26.4%39.2%26.8%
QoQ Delta Op Mgn LTM-0.2%-1.0%1.6%-0.0%0.6%
CFO/Rev LTM-26.3%-33.1%34.4%34.2%33.6%
CFO/Rev 3Y Avg-20.0%-37.5%32.0%31.9%31.9%
FCF/Rev LTM-23.4%-31.3%30.4%32.5%30.8%
FCF/Rev 3Y Avg-16.9%-36.0%28.2%30.0%29.1%

Valuation

SAVABIIBAVXLABBVAMGNGILDMedian
NameCassava .Biogen Anavex L.AbbVie Amgen Gilead S. 
Mkt Cap0.121.00.8382.3146.9138.079.5
P/S-2.1-6.64.24.84.5
P/EBIT-0.810.5-16.564.914.216.812.4
P/E-0.814.2-15.9101.622.221.918.0
P/CFO-1.18.1-20.619.812.214.010.2
Total Yield-122.0%7.0%-6.3%3.9%7.9%7.4%5.5%
Dividend Yield0.0%0.0%0.0%3.0%3.4%2.9%1.4%
FCF Yield 3Y Avg-44.1%6.6%-5.7%7.3%6.2%8.0%6.4%
D/E0.00.30.00.20.40.20.2
Net D/E-1.10.2-0.10.20.30.10.2

Returns

SAVABIIBAVXLABBVAMGNGILDMedian
NameCassava .Biogen Anavex L.AbbVie Amgen Gilead S. 
1M Rtn-10.7%3.7%-9.9%4.6%-7.9%-5.7%-6.8%
3M Rtn1.0%13.5%0.4%17.6%-5.1%3.4%2.2%
6M Rtn-25.1%0.4%-3.8%2.9%-12.8%2.0%-1.7%
12M Rtn-92.6%-28.0%57.2%14.4%-15.8%37.3%-0.7%
3Y Rtn-93.3%-31.0%-3.1%68.0%30.0%88.1%13.4%
1M Excs Rtn-13.1%1.2%-12.3%2.2%-10.3%-8.1%-9.2%
3M Excs Rtn-7.6%0.1%-5.4%4.8%-16.4%-8.8%-6.5%
6M Excs Rtn-41.2%-16.3%-19.0%-13.8%-28.9%-16.3%-17.7%
12M Excs Rtn-110.7%-45.5%53.9%-2.6%-32.6%20.5%-17.6%
3Y Excs Rtn-156.1%-94.6%-75.4%8.7%-41.1%28.7%-58.3%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/14/20255/8/20253/3/202511/7/20248/8/20245/10/20242/28/202411/7/20238/3/20235/1/20232/28/202311/7/2022
Key Financials Quarterly            
Total Revenue000000000000
Ebitda-45-24-30-30-61-20-24-27-28-26-22-21
Operating Income-45-25-30-31-61-20-24-28-29-27-22-21
Net Income-44-23-28-28625-21-26-26-24-19-20
EPS-0.92-0.48-0.57-0.580.130.58-0.50-0.61-0.63-0.58-0.47-0.51
Key Financials TTM            
Total Revenue TTM000000000000
Ebitda TTM-130-146-141-135-132-99-106-104-98-89-80-72
Operating Income TTM-131-147-142-136-133-101-107-106-99-90-81-74
Net Income TTM-123-73-24-18-15-48-97-95-90-83-76-71
Growth Rates Quarterly            
Total Revenue Growth------------
EBITDA Growth26.1%-24.2%-26.3%-10.5%-115.2%24.9%-8.2%-30.6%-44.7%-49.2%-55.8%-120.6%
Operating Income Growth26.1%-23.3%-25.5%-9.8%-113.4%24.8%-7.9%-30.6%-44.5%-48.8%-55.1%-118.9%
Net Income Growth-818.5%-193.5%-31.9%-8.9%123.3%203.2%-9.3%-26.6%-36.5%-38.5%-35.0%-111.8%
Margins Quarterly            
EBITDA Margin------------
Operating Income Margin------------
Net Income Margin------------
Cash & Debt            
Total Cash112117129149207124121142168187201175
Total Debt000000000000
Net Debt / (Cash)-112-117-129-149-207-124-121-142-168-187-201-174
Cash Flows Quarterly            
FCF from Operations-5-11-61-18-18-19-22-27-20-13-21-22
Cash Flows TTM            
FCF from Operations TTM-96-109-117-78-86-88-82-81-76-67-78-64
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-40.5%-22.4%-28.7%-31.0%-74.1%-25.7%-24.3%-29.9%-33.4%-32.7%-28.9%-29.6%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-29.2%-33.5%-33.7%-34.4%-40.3%-32.5%-27.0%-28.3%-28.7%-27.8%-26.3%-25.5%

Segment Financials

Assets by Segment

$ Mil20242023202220212020
Development of novel drugs and diagnostics1522352679423
Total1522352679423


Price Behavior

SAVA Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta1.662.311.980.800.790.99
Up Beta0.991.741.590.641.021.02
Down Beta-2.300.150.860.670.700.55
Up Capture339%416%241%89%-43%18%
Bmk +ve Days10223571142415
Stock +ve Days11223164116333
Down Capture265%263%259%112%120%107%
Bmk -ve Days11192754106334
Stock -ve Days10192957127411

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity6,130,991
Short Interest: % Change Since 8152025-1.8%
Average Daily Volume552,980
Days-to-Cover Short Interest11.09
Basic Shares Quantity48,308,000
Short % of Basic Shares12.7%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/14/20255.7%-6.1%-7.5%
3/3/20253.3%17.1%-37.5%
11/7/2024-4.6%-5.2%-87.9%
8/8/2024-13.8%-21.5%-10.9%
5/10/20241.9%14.3%-7.0%
2/28/2024-0.3%-6.9%-11.2%
11/7/20234.3%-8.8%1.5%
8/3/2023-0.7%-11.1%-0.0%
...
SUMMARY STATS   
# Positive795
# Negative121014
Median Positive5.5%6.6%11.0%
Median Negative-4.6%-14.5%-11.1%
Max Positive15.1%31.3%71.6%
Max Negative-13.8%-21.8%-87.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025814202510-Q 6/30/2025
3312025508202510-Q 3/31/2025
12312024303202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024808202410-Q 6/30/2024
3312024510202410-Q 3/31/2024
12312023228202410-K 12/31/2023
93020231107202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023501202310-Q 3/31/2023
12312022228202310-K 12/31/2022
93020221107202210-Q 9/30/2022
6302022804202210-Q 6/30/2022
3312022505202210-Q 3/31/2022
12312021301202210-K 12/31/2021
93020211115202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Kupiec James WilliamChief Medical Officer12032024Sell3.874,00015,480 Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.